Impact Factor 5.206 | CiteScore 4.82
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Cell Dev. Biol. | doi: 10.3389/fcell.2019.00169

Recent advances in understanding the reversal of gene silencing during X chromosome reactivation.

 Vincent Pasque1*,  Irene Talon1, Adrian Janiszewski1, Joel Chappell1 and Lotte Vanheer1
  • 1KU Leuven, Belgium

Dosage compensation between XX female and XY male cells is achieved by a process known as X chromosome inactivation (XCI) in mammals. XCI is initiated early during development in female cells and is subsequently stably maintained in most somatic cells. Despite its stability, the robust transcriptional silencing of XCI is reversible, in the embryo and also in a number of reprogramming settings. Although XCI has been intensively studied, the dynamics, factors and mechanisms of X chromosome reactivation (XCR) remain largely unknown. In this review, we discuss how new sequencing technologies and reprogramming approaches have enabled recent advances that revealed the timing of transcriptional activation during XCR. We also discuss the factors and chromatin features that might be important to understand the dynamics and mechanisms of the erasure of transcriptional gene silencing on the inactive X chromosome (Xi).

Keywords: Stem Cells, pluripotency, Epigenetic memory, X chromosome reactivation (XCR), X chromosome inactivation (XCI), Gene Silencing, Chromatin, epigenetics

Received: 03 Jun 2019; Accepted: 07 Aug 2019.

Copyright: © 2019 Pasque, Talon, Janiszewski, Chappell and Vanheer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Vincent Pasque, KU Leuven, Leuven, 3000, Belgium, vincent.pasque@kuleuven.be